Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
804 Views
eMediNexus 13 January 2023
Clinical trials have shown promising results for interleukin-23 inhibitors in treating psoriasis. These drugs have been used in clinical practice since 2017.
The present study investigated the drug survival and effectiveness of interleukin-23 inhibitors in treating psoriasis and psoriatic arthritis (PsA) in a real-world setting.
It was a retrospective analysis of patients treated with either guselkumab, tildrakizumab, or risankizumab during the period from June 11, 2018, to July 14, 2021.
The study observed-
This study shows that Interleukin-23 inhibitors have high and similar drug survival and effectiveness in patients with difficult-to-treat psoriasis and PsA.
Elgaard CDB, Iversen L, Hjuler KF. Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis. Journal of Dermatological Treatment. 2022. DOI: 10.1080/09546634.2022.2133531
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}